Allianz SE Sells 1,531 Shares of Stryker Corporation $SYK

Allianz SE cut its position in shares of Stryker Corporation (NYSE:SYK) by 34.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,860 shares of the medical technology company’s stock after selling 1,531 shares during the quarter. Allianz SE’s holdings in Stryker were worth $1,132,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of Stryker during the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD boosted its stake in Stryker by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Stryker by 66.7% in the 1st quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after buying an additional 549,643 shares during the period. Vanguard Group Inc. raised its stake in shares of Stryker by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after buying an additional 361,136 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Stryker by 13.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after buying an additional 261,058 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SYK. Weiss Ratings lowered shares of Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, November 7th. Redburn Partners set a $420.00 price target on shares of Stryker in a research note on Thursday, September 18th. Rothschild Redb upgraded Stryker to a “hold” rating in a research note on Thursday, September 18th. Wells Fargo & Company raised their target price on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Finally, Evercore ISI decreased their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Thirteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $433.37.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 over the last three months. Insiders own 5.20% of the company’s stock.

Stryker Stock Up 1.5%

Shares of NYSE SYK opened at $372.93 on Friday. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm’s 50-day simple moving average is $372.55 and its 200 day simple moving average is $381.18. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $142.62 billion, a price-to-earnings ratio of 49.40, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the company posted $2.87 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.